# Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

> **NCT06253650** · PHASE2 · RECRUITING · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 46 (estimated)

## Conditions studied

- Gastric Cancer
- HER2-positive Gastric Cancer

## Interventions

- **DRUG:** Experimental
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT06253650
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253650, "Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06253650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*